Antiviral potency of a siRNA targeting a conserved region of coxsackievirus A24

Coxsackievirus A24 (CVA24) is responsible for acute hemorrhagic conjunctivitis, a highly contagious eye disease for which no prevention or treatment is currently available. We thus assessed the antiviral potential of a small interfering RNA (siRNA) targeting CVA24. HeLa cells with or without four di...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2008-11, Vol.376 (2), p.389-394
Main Authors: Jun, Eun Jung, Nam, Young Ran, Ahn, Jeonghyun, Tchah, Hungwon, Joo, Chul Hyun, Jee, Youngmee, Kim, Yoo Kyum, Lee, Heuiran
Format: Article
Language:English
Subjects:
Acute hemorrhagic conjunctivitis
Antiviral Agents - pharmacology
Antiviral effect
Base Sequence
cis-Acting replication element
Conserved Sequence
Coxsackievirus
Coxsackievirus A24
Cytopathogenic Effect, Viral - drug effects
Enterovirus C, Human - drug effects
Enterovirus C, Human - genetics
Enterovirus C, Human - physiology
HeLa Cells
Humans
RNA, Small Interfering - genetics
RNA, Small Interfering - pharmacology
Small-interfering RNA
Virus Replication - drug effects
Virus Replication - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coxsackievirus A24 (CVA24) is responsible for acute hemorrhagic conjunctivitis, a highly contagious eye disease for which no prevention or treatment is currently available. We thus assessed the antiviral potential of a small interfering RNA (siRNA) targeting CVA24. HeLa cells with or without four different siRNAs complementary to 2C or 3D genome region, were challenged with various CVA24s. Among several siRNAs, a siRNA targeting the highly conserved genome region called the cis-acting replication element (CVA24-CRE), was the only siRNA that decreased virus replication and subsequent cytotoxicity by both CVA24 variant and clinical isolates. Furthermore, CVA24-CRE had effective antiviral activity against CVA24 in primary human conjunctival cells. In addition, CVA24-CRE was highly resistant to the emergence of genetically altered escape mutants. Collectively, the present study provides evidence that CVA24-CRE targeting a conserved viral genome region had universal, prolonged anti-CVA24 activity. This siRNA may thus hold a potential to act clinically as a novel anti-CVA24 agent.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2008.08.169